The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
- PMID: 37822353
- PMCID: PMC10563807
- DOI: 10.3389/bjbs.2023.11573
The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders
Abstract
Background: B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential diagnosis challenging. Therefore, accurate diagnosis is fundamental in particular for determining treatment options. Immunophenotyping by flow cytometry plays a crucial role in the diagnosis of B-LPDs. However, overlapping immunophenotyping patterns exist and the use of novel monoclonal antibodies has become increasingly important in immunophenotyping analysis. More recently differential expression of CD200 has been reported in various B-LPDs and that CD200 may improve the differentiation between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). In this study CD200 expression is evaluated in different B-LPDs. Methods: A total of 100 samples were collected and analysed by immunophenotyping flow cytometry over a period of 1 year (2017-2018), by a panel of monoclonal antibodies including CD200. The percentage of CD200 and its expression intensity was evaluated and compared between different groups of B-LPDs. Results: All of the 50 cases of CLL expressed CD200 with moderate to bright intensity, 6 MCL cases lacked the expression of CD200. Furthermore, all 5 cases of hairy cell leukaemia (HCL) expressed CD200. Out of all B-LPDs evaluated, CD200 expression in HCL cases was noted to be the brightest. The other 39 cases were not found to be B-LPDs. Conclusion: CD200 has an important role in differentiating CLL from MCL, HCL has a consistent bright expression of CD200. By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them.
Keywords: chronic lymphocytic leukaemia; flow cytometry; hairy cell leukaemia; immunophenotyping; mantle cell lymphoma.
Copyright © 2023 Al-Zubaidi and Hughes.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- WHO. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; (2017).
-
- WHO. Chronic Lymphocytic Leukemia Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. (2015).
-
- UK CR. Chronic Lymphocytic Leukaemia (CLL) Incidence Statistics (2015). Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/s... .
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
